Advertisement

Stereotactic body radiotherapy for the treatment of gynecologic malignancies: Passing fancy or here to stay?

  • Ryan J. Hutten
    Affiliations
    Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, UT 84112, United States of America
    Search for articles by this author
  • Y. Jessica Huang
    Affiliations
    Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, UT 84112, United States of America
    Search for articles by this author
  • David K. Gaffney
    Correspondence
    Corresponding author at: Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah Medical Center, 1950 Circle of Hope, Salt Lake City, UT 84112-5560, United States of America.
    Affiliations
    Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, UT 84112, United States of America
    Search for articles by this author
      Stereotactic body radiotherapy (SBRT) is defined as the delivery of image-guided high-dose conformal radiation, in five or fewer treatments. SBRT is established as a treatment option for select disease sites (lung, prostate, pancreas, hepatocellular), and has recently emerged as a promising treatment option in the setting of oligometasatic disease. Retrospective evidence supporting the utility of SBRT in gynecologic malignancies continues to grow however, practice patterns are widely variable [
      • Leung E.
      • Gladwish A.
      • Sahgal A.
      • et al.
      Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy.
      ]. Prospective randomized controlled trials demonstrating clinical benefits of SBRT for gynecologic malignancies are lacking.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leung E.
        • Gladwish A.
        • Sahgal A.
        • et al.
        Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy.
        Radiat. Oncol. Jan 30 2020; 15: 24https://doi.org/10.1186/s13014-020-1469-8
        • Palma D.A.
        • Olson R.
        • Harrow S.
        • et al.
        Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
        Lancet. May 18 2019; 393: 2051-2058https://doi.org/10.1016/S0140-6736(18)32487-5
        • Reshko L.B.
        • Baliga S.
        • Crandley E.F.
        • et al.
        Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
        Gynecol. Oncol. Dec 2020; 159: 611-617https://doi.org/10.1016/j.ygyno.2020.10.001
        • Onal C.
        • Gultekin M.
        • Oymak E.
        • et al.
        Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
        Int. J. Gynecol. Cancer. Jun 2020; 30: 865-872https://doi.org/10.1136/ijgc-2019-001115
        • Reddy A.V.
        • Mills M.N.
        • Reshko L.B.
        • Martin Richardson K.
        • Kersh C.R.
        Stereotactic body radiation therapy in oligometastatic uterine Cancer: clinical outcomes and toxicity.
        Cancer Investig. Sep 2020; 38: 522-530https://doi.org/10.1080/07357907.2020.1817483
        • Macchia G.
        • Lazzari R.
        • Colombo N.
        • et al.
        A large, multicenter, retrospective study on efficacy and safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic ovarian Cancer (MITO RT1 study): A collaboration of MITO, AIRO GYN, and MaNGO groups.
        Oncologist. Feb 2020; 25: e311-e320https://doi.org/10.1634/theoncologist.2019-0309
        • Yegya-Raman N.
        • Cao C.D.
        • Hathout L.
        • et al.
        Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review.
        Gynecol. Oncol. Nov 2020; 159: 573-580https://doi.org/10.1016/j.ygyno.2020.08.010
        • Park H.J.
        • Chang A.R.
        • Seo Y.
        • et al.
        Stereotactic body radiotherapy for recurrent or Oligometastatic uterine cervix Cancer: A cooperative study of the Korean radiation oncology group (KROG 14-11).
        Anticancer Res. Sep 2015; 35: 5103-5110
        • Bignardi M.
        • Navarria P.
        • Mancosu P.
        • et al.
        Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases.
        Int. J. Radiat. Oncol. Biol. Phys. Nov 1 2011; 81: 831-838https://doi.org/10.1016/j.ijrobp.2010.05.032
        • Kunos C.A.
        • Brindle J.
        • Waggoner S.
        • et al.
        Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies.
        Front. Oncol. 2012; 2: 181https://doi.org/10.3389/fonc.2012.00181
        • Bonomo P.
        • Cipressi S.
        • Saieva C.
        • et al.
        Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases.
        Tumori. Sep-Oct 2013; 99: 611-616https://doi.org/10.1700/1377.15311
        • Zhang T.W.
        • Palma D.
        • D’Souza D.
        • Velker V.
        • Mendez L.C.
        Stereotactic ablative radiotherapy for recurrent or metastatic gynecological cancer: extending lives?.
        Curr. Treat. Options in Oncol. Jun 12 2020; 21: 58https://doi.org/10.1007/s11864-020-00748-6
        • Choi C.W.
        • Cho C.K.
        • Yoo S.Y.
        • et al.
        Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer.
        Int. J. Radiat. Oncol. Biol. Phys. May 1 2009; 74: 147-153https://doi.org/10.1016/j.ijrobp.2008.07.020
        • Mesko S.
        • Sandler K.
        • Cohen J.
        • Konecny G.
        • Steinberg M.
        • Kamrava M.
        Clinical outcomes for stereotactic ablative radiotherapy in Oligometastatic and Oligoprogressive gynecological malignancies.
        Int. J. Gynecol. Cancer. Feb 2017; 27: 403-408https://doi.org/10.1097/igc.0000000000000869
        • Iftode C.
        • DʼAgostino GR, Tozzi A, et al.
        Stereotactic body radiation therapy in Oligometastatic ovarian Cancer: A promising therapeutic approach.
        Int. J. Gynecol. Cancer. Oct 2018; 28: 1507-1513https://doi.org/10.1097/igc.0000000000001324
        • Lazzari R.
        • Ronchi S.
        • Gandini S.
        • et al.
        Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday.
        Int. J. Radiat. Oncol. Biol. Phys. Jul 1 2018; 101: 650-660https://doi.org/10.1016/j.ijrobp.2018.03.058
        • Kowalchuk R.O.
        • Waters M.R.
        • Richardson K.M.
        • et al.
        Stereotactic body radiation therapy in the treatment of ovarian cancer.
        Radiat. Oncol. May 13 2020; 15: 108https://doi.org/10.1186/s13014-020-01564-w
        • Jacobson G.
        • Galvan-Turner V.
        Rethinking the role of radiation therapy in the management of epithelial ovarian cancer.
        Diagnostics (Basel). Apr 11 2020; 10https://doi.org/10.3390/diagnostics10040211
        • Deodato F.
        • Macchia G.
        • Grimaldi L.
        • et al.
        Stereotactic radiotherapy in recurrent gynecological cancer: a case series.
        Oncol. Rep. Aug 2009; 22: 415-419
        • Hasan S.
        • Ricco A.
        • Jenkins K.
        • et al.
        Survival and control prognosticators of recurrent gynecological malignancies of the pelvis and Para-aortic region treated with stereotactic body radiation therapy.
        Front. Oncol. 2016; 6: 249https://doi.org/10.3389/fonc.2016.00249
        • Abusaris H.
        • Hoogeman M.
        • Nuyttens J.J.
        Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region.
        Technol Cancer Res Treat. Dec 2012; 11: 591-597https://doi.org/10.7785/tcrt.2012.500261
        • Guckenberger M.
        • Bachmann J.
        • Wulf J.
        • et al.
        Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer.
        Radiother. Oncol. Jan 2010; 94: 53-59https://doi.org/10.1016/j.radonc.2009.12.004
        • Seo Y.
        • Kim M.S.
        • Yoo H.J.
        • et al.
        Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: feasibility and complication.
        Asia Pac J Clin Oncol. Jun 2016; 12: e280-e288https://doi.org/10.1111/ajco.12185
        • Mendez L.C.
        • Leung E.
        • Cheung P.
        • Barbera L.
        The role of stereotactic ablative body radiotherapy in Gynaecological cancers: A systematic review.
        Clin Oncol (R Coll Radiol). Jun 2017; 29: 378-384https://doi.org/10.1016/j.clon.2017.01.009
        • Kamrava M.
        • Chino J.P.
        • Beriwal S.
        SAbR as an alternative boost modality for cervical cancer: a cautionary exercise.
        Int. J. Radiat. Oncol. Biol. Phys. Mar 1 2020; 106: 472-474https://doi.org/10.1016/j.ijrobp.2019.11.026
        • Cilla S.
        • Macchia G.
        • Mattiucci G.
        • et al.
        Optimized stereotactic volumetric modulated arc therapy as an alternative to brachytherapy for vaginal cuff boost. A dosimetric study.
        Med. Dosim. Winter 2020; 45: 352-358https://doi.org/10.1016/j.meddos.2020.05.003
        • Albuquerque K.
        • Tumati V.
        • Lea J.
        • et al.
        A phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer.
        Int. J. Radiat. Oncol. Biol. Phys. Mar 1 2020; 106: 464-471https://doi.org/10.1016/j.ijrobp.2019.10.042
        • Ito K.
        • Kito S.
        • Nakajima Y.
        • et al.
        Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study.
        Jpn. J. Clin. Oncol. Sep 1 2019; 49: 856-861https://doi.org/10.1093/jjco/hyz074
        • Cheng H.Y.
        • Liang J.A.
        • Hung Y.C.
        • et al.
        Stereotactic body radiotherapy for pelvic boost in gynecological cancer patients with local recurrence or unsuitable for intracavitary brachytherapy.
        Taiwan J Obstet Gynecol. Jan 2021; 60: 111-118https://doi.org/10.1016/j.tjog.2020.11.017